About talazoparib tosylate
PARP inhibitor anticancer medicine
Used for
- Treats certain inherited BRCA-mutated, HER2-negative advanced breast cancers.
- Used alone or with enzalutamide for certain BRCA-mutated, metastatic castration-resistant prostate cancers.
Usual adult dose
Breast cancer: 1 mg by mouth once daily. With enzalutamide for prostate cancer: 0.5 mg once daily; doses may need reduction for kidney problems or side effects.
Common side effects
- Low blood cell counts, including anemia, low platelets, and low white blood cells.
- Nausea, tiredness, decreased appetite, and diarrhea.
- Hair loss, headache, and vomiting.
Important warnings
- Can cause severe bone marrow suppression; blood tests are needed during treatment.
- Rarely causes myelodysplastic syndrome or acute myeloid leukemia.
- Can harm an unborn baby; effective contraception is needed during treatment.
- Prostate cancer treatment also requires a gonadotropin-releasing hormone medicine or prior orchiectomy.
Pregnancy
May cause fetal harm. Avoid pregnancy during treatment; follow product-label contraception guidance.
Breastfeeding
Do not breastfeed during treatment and for one month after the final dose.
Interactions
- Strong P-glycoprotein inhibitors can increase talazoparib levels and may require dose adjustment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.